Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Other Accumulated Expenses (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed Other Accumulated Expenses for 10 consecutive years, with $82000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Accumulated Expenses fell 56.84% year-over-year to $82000.0, compared with a TTM value of $82000.0 through Sep 2025, down 56.84%, and an annual FY2024 reading of $120000.0, down 49.15% over the prior year.
  • Other Accumulated Expenses was $82000.0 for Q3 2025 at Spero Therapeutics, down from $89000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $1.3 million in Q3 2021 and bottomed at $82000.0 in Q3 2025.
  • Average Other Accumulated Expenses over 5 years is $404842.1, with a median of $208000.0 recorded in 2024.
  • The sharpest move saw Other Accumulated Expenses skyrocketed 468.25% in 2023, then crashed 84.15% in 2024.
  • Year by year, Other Accumulated Expenses stood at $1.2 million in 2021, then crashed by 83.17% to $209000.0 in 2022, then rose by 12.92% to $236000.0 in 2023, then plummeted by 49.15% to $120000.0 in 2024, then crashed by 31.67% to $82000.0 in 2025.
  • Business Quant data shows Other Accumulated Expenses for SPRO at $82000.0 in Q3 2025, $89000.0 in Q2 2025, and $102000.0 in Q1 2025.